[1] 付 静,李志军.药物性肝病的发病机制及治疗新进展[J].天津医药,2009,37(4):333.
[2] 王 文,于 红. 61例药物性肝病临床特点与转归分析[J].实用肝病学杂志,2008,11(3):191.
[3] Chang CY, Schiano TD. Drug hepatotoxicity[J]. Aliment Pharmacol Ther, 2007,25:1135.
[4] Hayes BD, Klein-Schwartz W, Barrueto Jr F. Polypharmacy and the geriatric patient[J]. Clin Geriatr Med, 2007,23: 371.
[5] Onji M, Fujioka S, Takeuchi Y, et al. Clinical characteristics of drug-induced liver injury in the elderly[J]. Hepatol Res, 2009,39:546.
[6] Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury[J]. World J Gastroenterol ,2008,14:6774.
[7] Nathwani RA, Kaplowitz N. Drug hepatotoxicity[J]. Clin Liver Dis ,2006,10:207.
[8] Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview[J]. Expert Opin Drug Saf, 2007,6:673.
[9] Taggart HM, Alderdice JM. Fatal cholestatic jaundice in elderly patients taking benoxaprofen[J]. BMJ, 1982,284:1372.
[10] 马 琳,刘 波. 85例老年药物型肝炎患者临床分析[J]. 实用肝病杂志, 2011, 14(1):45.
[11] 王 林,张人凤,金 鸿,等.药物性肝损害90例临床分析[J]. 临床荟萃, 2011 ,26 (2):162.
[12] 徐列明,林庆勋.正确认识中药的肝毒性[J]. 中华肝病杂志, 2007,15(7):534.
[13] Lucena MI, Andrade RJ, Ferna'ndez MC, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain[J]. Hepatology, 2006,44:850.
[14] Kaplowitz N. Idiosyncratic drug hepatotoxicity[J]. Nat Rev Drug Discov,2005,4:489.
[15] Chien RN, Yang LJ, Lin PY, et al. Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study[J]. Hepatology, 1997,25:103.
[16] Stricker BH, Blok AP, Claas FH, et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases[J]. Hepatology, 1988,8:59.
[17] Raúl J Andrade, Paul M, Tulkens J. Hepatic safety of antibiotics used in primary care[J]. J Antimicrob Chemother, 2011, 66: 1431.
[18] Hagley MT, Hulisz DT, Burns CM. Hepatotoxicity associated with angiotensin-converting enzyme inhibitorset[J]. Ann Pharmacother, 1993,27:228.
[19] Andrade RJ, Lucena MI, Ferna'ndez MC, et al. Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity[J]. Eur J Gastroenterol Hepatol, 2002,14:887.
[20] Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors[J]. Drug Saf ,2000,23:197.
[21] Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial[J]. Am J Gastroenterol, 2009,104:356.
[22] Lewis JH, Schiff ER. Methotrexate-induced chronic liver injury: guidelines for detection and prevention[J]. Am J Gastroenterol,1988,88:1337.